|
1
|
Larsson C: Protein kinase C and the
regulation of the actin cytoskeleton. Cell Signal. 18:276–284.
2006. View Article : Google Scholar
|
|
2
|
Kalwa H and Michel T: The MARCKS protein
plays a critical role in phosphatidylinositol 4,5-bisphosphate
metabolism and directed cell movement in vascular endothelial
cells. J Biol Chem. 286:2320–2330. 2011. View Article : Google Scholar :
|
|
3
|
Aderem A: The MARCKS brothers: A family of
protein kinase C substrates. Cell. 71:713–716. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McNamara RK and Lenox RH: Distribution of
the protein kinase C substrates MARCKS and MRP in the postnatal
developing rat brain. J Comp Neurol. 397:337–356. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Underhill DM, Chen J, Allen LA and Aderem
A: MacMARCKS is not essential for phagocytosis in macrophages. J
Biol Chem. 273:33619–33623. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yue L, Lu S, Garces J, Jin T and Li J:
Protein kinase C-regulated dynamitin-macrophage-enriched
myristoylated alanine-rice C kinase substrate interaction is
involved in macrophage cell spreading. J Biol Chem.
275:23948–23956. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arbuzova A, Schmitz AA and Vergères G:
Cross-talk unfolded: MARCKS proteins. Biochem J. 362:1–12. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Björkblom B, Padzik A, Mohammad H,
Westerlund N, Komulainen E, Hollos P, Parviainen L, Papageorgiou
AC, Iljin K, Kallioniemi O, et al: c-Jun N-terminal kinase
phosphorylation of MARCKSL1 determines actin stability and
migration in neurons and in cancer cells. Mol Cell Biol.
32:3513–3526. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li T, Li D, Sha J, Sun P and Huang Y:
MicroRNA-21 directly targets MARCKS and promotes apoptosis
resistance and invasion in prostate cancer cells. Biochem Biophys
Res Commun. 383:280–285. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim BR, Dong SM, Seo SH, Lee JH, Lee JM,
Lee SH and Rho SB: Lysyl oxidase-like 2 (LOXL2) controls
tumor-associated cell proliferation through the interaction with
MARCKSL1. Cell Signal. 26:1765–1773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Folkman J and Shing Y: Angiogenesis. J
Biol Chem. 267:10931–10934. 1992.PubMed/NCBI
|
|
12
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ferrara N: VEGF and the quest for tumour
angiogenesis factors. Nat Rev Cancer. 2:795–803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Gijn ME, Daemen MJ, Smits JF and
Blankesteijn WM: The wnt-frizzled cascade in cardiovascular
disease. Cardiovasc Res. 55:16–24. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cohen ED, Tian Y and Morrisey EE: Wnt
signaling: An essential regulator of cardiovascular
differentiation, morphogenesis and progenitor self-renewal.
Development. 135:789–798. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zerlin M, Julius MA and Kitajewski J:
Wnt/Frizzled signaling in angiogenesis. Angiogenesis. 11:63–69.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dejana E, Tournier-Lasserve E and
Weinstein BM: The control of vascular integrity by endothelial cell
junctions: Molecular basis and pathological implications. Dev Cell.
16:209–221. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franco CA, Liebner S and Gerhardt H:
Vascular morphogenesis: A Wnt for every vessel? Curr Opin Genet
Dev. 19:476–483. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dejana E: The role of wnt signaling in
physiological and pathological angiogenesis. Circ Res. 107:943–952.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mustonen T and Alitalo K: Endothelial
receptor tyrosine kinases involved in angiogenesis. J Cell Biol.
129:895–898. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Breier G: Endothelial receptor tyrosine
kinases involved in blood vessel development and tumor
angiogenesis. Adv Exp Med Biol. 476:57–66. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ferrara N: Role of vascular endothelial
growth factor in regulation of physiological angiogenesis. Am J
Physiol Cell Physiol. 280:C1358–C1366. 2001.PubMed/NCBI
|
|
23
|
Meyer RD and Rahimi N: Comparative
structure-function analysis of VEGFR-1 and VEGFR-2: What have we
learned from chimeric systems? Ann NY Acad Sci. 995:200–207. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meyer RD, Singh A, Majnoun F, Latz C,
Lashkari K and Rahimi N: Substitution of C-terminus of VEGFR-2 with
VEGFR-1 promotes VEGFR-1 activation and endothelial cell
proliferation. Oncogene. 23:5523–5531. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yang Y, Zhang Y, Cao Z, Ji H, Yang X,
Iwamoto H, Wahlberg E, Länne T, Sun B and Cao Y: Anti-VEGF- and
anti-VEGF receptor-induced vascular alteration in mouse healthy
tissues. Proc Natl Acad Sci USA. 110:12018–12023. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cao Y: VEGF-targeted cancer
therapeutics-paradoxical effects in endocrine organs. Nat Rev
Endocrinol. 10:530–539. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee OH, Kim YM, Lee YM, Moon EJ, Lee DJ,
Kim JH, Kim KW and Kwon YG: Sphingosine 1-phosphate induces
angiogenesis: Its angiogenic action and signaling mechanism in
human umbilical vein endothelial cells. Biochem Biophys Res Commun.
264:743–750. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee JH, Chun T, Park SY and Rho SB:
Interferon regulatory factor-1 (IRF-1) regulates VEGF-induced
angiogenesis in HUVECs. Biochim Biophys Acta. 1783:1654–1662. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rho SB, Lee KH, Kim JW, Shiba K, Jo YJ and
Kim S: Interaction between human tRNA synthetases involves repeated
sequence elements. Proc Natl Acad Sci USA. 93:10128–10133. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rho SB, Kim MJ, Lee JS, Seol W, Motegi H,
Kim S and Shiba K: Genetic dissection of protein-protein
interactions in multi-tRNA synthetase complex. Proc Natl Acad Sci
USA. 96:4488–4493. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rho SB, Song YJ, Lim MC, Lee SH, Kim BR
and Park SY: Programmed cell death 6 (PDCD6) inhibits angiogenesis
through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cell
Signal. 24:131–139. 2012. View Article : Google Scholar
|
|
32
|
Plate KH, Breier G, Weich HA and Risau W:
Vascular endothelial growth factor is a potential tumour
angiogenesis factor in human gliomas in vivo. Nature. 359:845–848.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Downward J: Signal transduction. A target
for PI(3) kinase. Nature. 376:553–554. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Khwaja A: Akt is more than just a Bad
kinase. Nature. 401:33–34. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Guertin DA and Sabatini DM: An expanding
role for mTOR in cancer. Trends Mol Med. 11:353–361. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ramakrishnan S, Subramanian IV, Yokoyama Y
and Geller M: Angiogenesis in normal and neoplastic ovaries.
Angiogenesis. 8:169–182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kumaran GC, Jayson GC and Clamp AR:
Antiangiogenic drugs in ovarian cancer. Br J Cancer. 100:1–7. 2009.
View Article : Google Scholar :
|
|
38
|
Alvarez AA, Krigman HR, Whitaker RS, Dodge
RK and Rodriguez GC: The prognostic significance of angiogenesis in
epithelial ovarian carcinoma. Clin Cancer Res. 5:587–591.
1999.PubMed/NCBI
|
|
39
|
Hazelton D, Nicosia RF and Nicosia SV:
Vascular endothelial growth factor levels in ovarian cyst fluid
correlate with malignancy. Clin Cancer Res. 5:823–829.
1999.PubMed/NCBI
|
|
40
|
Ko YB, Kim BR, Yoon K, Choi EK, Seo SH,
Lee Y, Lee MA, Yang JB, Park MS and Rho SB: WIF1 can effectively
co-regulate pro-apoptotic activity through the combination with
DKK1. Cell Signal. 26:2562–2572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
Therapeutic implications. Semin Oncol. 29(Suppl 16): S10–S14. 2002.
View Article : Google Scholar
|
|
42
|
Mu J, Abe Y, Tsutsui T, Yamamoto N, Tai
XG, Niwa O, Tsujimura T, Sato B, Terano H, Fujiwara H, et al:
Inhibition of growth and metastasis of ovarian carcinoma by
administering a drug capable of interfering with vascular
endothelial growth factor activity. Jpn J Cancer Res. 87:963–971.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hartenbach EM, Olson TA, Goswitz JJ,
Mohanraj D, Twiggs LB, Carson LF and Ramakrishnan S: Vascular
endothelial growth factor (VEGF) expression and survival in human
epithelial ovarian carcinomas. Cancer Lett. 121:169–175. 1997.
View Article : Google Scholar
|
|
44
|
Yamamoto S, Konishi I, Mandai M, Kuroda H,
Komatsu T, Nanbu K, Sakahara H and Mori T: Expression of vascular
endothelial growth factor (VEGF) in epithelial ovarian neoplasms:
Correlation with clinicopathology and patient survival, and
analysis of serum VEGF levels. Br J Cancer. 76:1221–1227. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ferrara N and Davis-Smyth T: The biology
of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Park ST, Kim BR, Park SH, Lee JH, Lee EJ,
Lee SH and Rho SB: Suppression of VEGF expression through
interruption of the HIF-1α and Akt signaling cascade modulates the
anti-angiogenic activity of DAPK in ovarian carcinoma cells. Oncol
Rep. 31:1021–1029. 2014.
|
|
47
|
Gerber HP, Kowalski J, Sherman D, Eberhard
DA and Ferrara N: Complete inhibition of rhabdomyosarcoma xenograft
growth and neovascularization requires blockade of both tumor and
host vascular endothelial growth factor. Cancer Res. 60:6253–6258.
2000.PubMed/NCBI
|
|
48
|
Kerbel RS: New targets, drugs, and
approaches for the treatment of cancer: An overview. Cancer
Metastasis Rev. 17:145–147. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Semenza GL: Regulation of mammalian
O2 homeostasis by hypoxia-inducible factor 1. Annu Rev
Cell Dev Biol. 15:551–578. 1999. View Article : Google Scholar
|
|
50
|
Semenza GL: Hypoxia, clonal selection, and
the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol.
35:71–103. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhong H, De Marzo AM, Laughner E, Lim M,
Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons
JW: Overexpression of hypoxia-inducible factor 1alpha in common
human cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
52
|
Maxwell PH, Dachs GU, Gleadle JM, Nicholls
LG, Harris AL, Stratford IJ, Hankinson O, Pugh CW and Ratcliffe PJ:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fang J, Xia C, Cao Z, Zheng JZ, Reed E and
Jiang BH: Apigenin inhibits VEGF and HIF-1 expression via
PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB J. 19:342–353. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Altomare DA, Wang HQ, Skele KL, De Rienzo
A, Klein-Szanto AJ, Godwin AK and Testa JR: AKT and mTOR
phosphorylation is frequently detected in ovarian cancer and can be
targeted to disrupt ovarian tumor cell growth. Oncogene.
23:5853–5857. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hanrahan AJ, Schultz N, Westfal ML, Sakr
RA, Giri DD, Scarperi S, Janakiraman M, Olvera N, Stevens EV, She
QB, et al: Genomic complexity and AKT dependence in serous ovarian
cancer. Cancer Discov. 2:56–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
